ArticlePsychopharmacology2021
Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls.
Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Prevalence and Associated Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease Across Obesity Metabolic Phenotypes in Chronic Schizophrenia.International journal of general medicine · 2026Article
- Neural and somatic mechanisms driving clinical improvements in post-acute schizophrenia spectrum disorders.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Patient Life Engagement and Metabolic Profile Improve After Switching from First-/Second-Generation Antipsychotics to Brexpiprazole: A Real-World Study in Patients with Schizophrenia.Journal of personalized medicine · 2025Article
- Body mass index-specific metabolic profiles in schizophrenia: implications for cognitive dysfunction and psychopathology.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia.Annals of general psychiatry · 2024Article
- Multimorbidity and the Etiology of Schizophrenia.Current psychiatry reports · 2024Review
- The Bidirectional Relationship between Weight Gain and Cognitive Function in First-Episode Schizophrenia: A Longitudinal Study in China.Brain sciences · 2024Article
- Sex differences in the association between metabolic disorder and inflammatory cytokines in Han Chinese patients with chronic schizophrenia.Frontiers in psychiatry · 2024Article
- Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review.Frontiers in psychiatry · 2024Review
- Association between increased BMI and cognitive function in first-episode drug-naïve male schizophrenia.Frontiers in psychiatry · 2024Article
- Causal relationships between blood lipids and major psychiatric disorders: Univariable and multivariable mendelian randomization analysis.BMC medical genomics · 2023Article
- Association between Empathy and Clinical Symptoms among Overweight and Non-Overweight Chinese Chronic Schizophrenia Patients.Brain sciences · 2023Article
- Review
- Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management.Healthcare (Basel, Switzerland) · 2022Article
- Gray matter reduction in bilateral insula mediating adverse psychiatric effects of body mass index in schizophrenia.BMC psychiatry · 2022Article
- Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study.European journal of medical research · 2022Article
- Metabolic indexes of obesity in patients with common mental disorders in stable stage.BMC psychiatry · 2022Article
- Prevalence of Heavy Menstrual Bleeding and Its Associated Cognitive Risks and Predictive Factors in Women With Severe Mental Disorders.Frontiers in pharmacology · 2022Article
- Does Schizophrenia Itself Cause Obesity?Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectivePeople with schizophrenia exhibit a high obesity rate. However, little is known about the prevalence of obesity and its relationship with clinical symptoms and metabolic indicators in first-episode drug-naïve (FEDN) schizophrenia.
methodsDemographic and lipid parameters were gathered from 297 FEDN schizophrenia and 325 healthy controls. The patients' symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS).
resultsThe obesity rate of FEDN patients was 10.77%, similar to that of controls (10.5%). The prevalence of overweight plus obesity of patients was 44.8%, significantly higher than that of controls (36.6%). Compared with non-obese patients, obese patients had higher levels of cholesterol (4.81 ± 0.93 vs 4.22 ± 1.00 mmol/L), triglyceride (0.27 ± 0.21 vs 0.14 ± 0.24 mg/dL), low-density lipoprotein (0.48 ± 0.12 vs 0.40 ± 0.12 mg/dL), greater ratio of triglyceride/high-density lipoprotein (2.01 ± 1.23 vs 1.44 ± 1.26), and higher PANSS positive symptom subscale score (29.81 ± 6.29 vs 27.05 ± 6.15), general psychopathology subscale score (70.75 ± 11.74 vs 66.87 ± 11.37), and total score (149.81 ± 21.08 vs 140.64 ± 21.58), but lower high-density lipoprotein level (1.09 ± 0.21 vs 1.27 ± 0.34 mg/dL) (all p < 0.05). Correlation analysis revealed that body mass index (BMI) was positively correlated with triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride/high-density lipoprotein ratio, PANSS positive symptoms, general psychopathology, and total scores (all p < 0.05, r = 0.124 ~ 0.335). Multiple regression analysis confirmed that PANSS positive symptoms, total score, and cholesterol level were significantly associated with BMI (all p < 0.05, β: 0.126-0.162).
conclusionThere was no significant difference in the prevalence of obesity between FEDN patients and the control group. Moreover, BMI was positively associated with positive symptom severity in FEDN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.